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Abstract
Background: Medulloblastoma is the most common malignant brain tumor of childhood. Children who
relapse usually die of their disease, which reflects resistance to radiation and/or chemotherapy.
Improvements in outcome require a better understanding of the molecular basis of medulloblastoma
growth and treatment response. TP73 is a member of the TP53 tumor suppressor gene family that has
been found to be overexpressed in a variety of tumors and mediates apoptotic responses to genotoxic
stress. In this study, we assessed expression of TP73 RNA species in patient tumor specimens and in
medulloblastoma cell lines, and manipulated expression of full-length TAp73 and amino-terminal truncated
ΔNp73 to assess their effects on growth.
Methods: We analyzed medulloblastoma samples from thirty-four pediatric patients and the established
medulloblastoma cell lines, Daoy and D283MED, for expression of TP73 RNA including the full-length
transcript and the 5'-terminal variants that encode the ΔNp73 isoform, as well as TP53 RNA using
quantitative real time-RTPCR. Protein expression of TAp73 and ΔNp73 was quantitated with
immunoblotting methods. Clinical outcome was analyzed based on TP73 RNA and p53 protein expression.
To determine effects of overexpression or knock-down of TAp73 and ΔNp73 on cell cycle and apoptosis,
we analyzed transiently transfected medulloblastoma cell lines with flow cytometric and TUNEL methods.
Results: Patient medulloblastoma samples and cell lines expressed full-length and 5'-terminal variant TP73
RNA species in 100-fold excess compared to non-neoplastic brain controls. Western immunoblot analysis
confirmed their elevated levels of TAp73 and amino-terminal truncated ΔNp73 proteins. Kaplan-Meier
analysis revealed trends toward favorable overall and progression-free survival of patients whose tumors
display TAp73 RNA overexpression. Overexpression of TAp73 or ΔNp73 induced apoptosis under basal
growth conditions in vitro and sensitized them to cell death in response to chemotherapeutic agents.
Conclusion: These results indicate that primary medulloblastomas express significant levels of TP73
isoforms, and suggest that they can modulate the survival and genotoxic responsiveness of
medulloblastomas cells.
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Background
Medulloblastoma is the most common malignant brain
tumor of childhood [1,2]. Treatment with surgery, radia-
tion, and chemotherapy successfully cures many patients,
but survivors can suffer significant long-term toxicities
affecting their neurocognitive and growth potential [3].
Despite clinical advances, up to 30% of children with
medulloblastoma experience tumor progression or recur-
rence, for which no curative therapy exists. The lack of
more effective, less toxic therapies stems from our imper-
fect understanding of the molecular processes that under-
lie medulloblastoma growth.
Although the TP53 tumor suppressor gene (17p13.1) is
mutated in approximately half of human malignancies, it
is rarely mutated in medulloblastoma [4-7]. However,
several lines of evidence suggest that the TP53 pathway is
perturbed in medulloblastoma. Frank et al. have described
abnormalities of the p53-p14ARF pathway in the large cell/
anaplastic variant of medulloblastoma [8,9]. Our collab-
orators have noted significant nuclear p53 immunoposi-
tivity consistent with its accumulation and potential
mutation in approximately 50% of primary human
medulloblastoma examined [A. Adesina, personal com-
munication]. Deletion of the murine homolog, Trp53, in
the  Patched  haploinsufficient (Ptch+/-) mouse model
increases the incidence of spontaneous medulloblastoma
from approximately 15% to 100% [10]. Individuals with
Li-Fraumeni syndrome who carry germline TP53 muta-
tions are at increased risk for developing medulloblast-
oma, but fewer than 10% of sporadic medulloblastoma
display TP53 mutations [11,12]. There is also evidence
that the activity of p53 is regulated by alternate mecha-
nisms as observed in other cancers with wild-type TP53 [4].
While mutation of TP53 itself might not be frequently
involved, genes related to TP53 may play a role in medul-
loblastoma [8]. TP73 is a member of the TP53 gene fam-
ily. Full-length TP73-encoded protein, TAp73, is similar in
structure and shares functions with p53 as a candidate
tumor suppressor. It is able to activate p53-responsive
genes and to induce apoptosis in vitro [13]. Differential
transcription and alternative splicing of TP73 gives rise to
at least 35 distinct RNA species and 14 described protein
isoforms. Several 5'-variant RNA species (ΔNp73, ΔN'p73,
ΔEx2p73, and ΔEx2/3p73) are translated into the amino-
terminal truncated isoform, ΔNp73, which displays anti-
apoptotic effects in tumor cells and primary neurons (Fig-
ure 1A) [14,15]. Importantly, several recent studies have
demonstrated correlation between the relative expression
of TA and/or ΔNp73 isoforms with patient survival for a
variety of epithelial cancers occurring in adult patients
[16-19].
Primary medulloblastoma specimens and medulloblastoma  cell lines overexpress TAp73 and ΔNp73 RNA species rela- tive to TP53 Figure 1
Primary medulloblastoma specimens and medullob-
lastoma cell lines overexpress TAp73 and ΔNp73 
RNA species relative to TP53. (A) TP73 gene and rela-
tive location of isoform-specific primers for qRT-RTPCR of 
TP73. Exons are depicted as boxes with overlying arrows 
corresponding to location of primers for PCR. (B) Estab-
lished medulloblastoma cell lines, Daoy and D283MED 
(D283), and human adult cerebellum (Cbl) express high lev-
els of TAp73 and amino-terminal splice variants encoding 
ΔNp73 in comparison to human fetal brain. Primary medul-
loblastoma (MB) samples from patients (n = 34) display simi-
lar overexpression of TAp73 and ΔNp73 RNA species. (C) 
Primary medulloblastoma samples from patients (n = 34) dis-
play overexpression of TAp73 and amino-terminal truncated 
TP73 RNA variants, relative to human fetal brain and normal-
ized to GAPDH expression. By comparison, TP53 RNA is rel-
atively underexpressed. Total ΔNp73 represents the sum of 
expression of all amino-terminal-truncated TP73 RNA vari-
ants (ΔNp73, ΔN'p73, ΔEx2p73, and ΔEx2/3p73). Columns, 
mean expression of at least 2 experiments; error bars, ± 
S.E.M. Y-axis, RNA expression relative to human fetal brain 
and normalized to GAPDH expression (N.B. log-scale).BMC Cancer 2007, 7:127 http://www.biomedcentral.com/1471-2407/7/127
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Surveys have demonstrated overexpression of TP73 RNA
in malignancies including colon and hepatocellular carci-
noma, and neuroblastoma [20-22]. Neurodevelopmental
pathways of clinical significance in neuroblastoma have
also been implicated in medulloblastoma. A limited scale
study failed to detect loss of heterozygosity or mutation of
TP73 in five medulloblastoma samples [23]. However, to
date no studies have examined the relative expression of
TAp73 and ΔNp73 in medulloblastoma.
Here we report TP73 overexpression in a series of primary
human medulloblastoma and in established medullob-
lastoma cell lines, relative to normal brain tissue. Kaplan-
Meier analysis revealed trends toward favorable overall
and progression-free survival of patients whose tumors
display TAp73 RNA overexpression. Functional data indi-
cate that overexpression of TAp73β and ΔNp73β induces
apoptosis in transfected medulloblastoma cells with wild-
type TP53. These results support the hypothesis that
medulloblastoma express significant levels of p73 iso-
forms that can modulate survival. Our results support a
role for TP73 in the growth of medulloblastoma and its
response to genotoxic therapies.
Methods
Primary medulloblastoma specimens and 
medulloblastoma cell lines
Thirty-four medulloblastoma samples were obtained
from children diagnosed between 1996 and 2004 at Texas
Children's Hospital (Houston, TX) upon informed con-
sent for an institutional review board-approved protocol
(Table 1). All specimens were obtained at the time of diag-
nosis, snap-frozen and stored in liquid nitrogen. Histo-
logic diagnoses were confirmed by pathologic review
according to WHO criteria [12].
Gross total resection was achieved in twenty-four patients.
Chemotherapy for most patients consisted of cisplatin
and vincristine, with combinations of carboplatin, etopo-
side, cyclophosphamide or lomustine. Sixteen patients
received intensified chemotherapy with autologous stem
cell support [24-27]. Patients greater than 36 months old
received craniospinal irradiation 2400 ± 360 centiGray
(cGy) with a tumor dose of 5300 ± 720 cGy. Median age
at diagnosis was 78.9 months (range 12–216; mean 84 ±
4.3 months (± S.E.M.)) with median follow up of 42
months (range 4–88; mean 45 ± 3.9 months). For survival
analysis, patients were stratified into two groups based on
the median expression of TAp73 RNA in primary medul-
loblastoma tumor samples.
Established human medulloblastoma cell lines, Daoy and
D283MED (D283), (American Type Culture Collection,
Manassas, VA) were maintained in Dulbecco's modified
Eagle's medium (Invitrogen, Carlsbad, CA) with high glu-
cose (6 g/liter), 2 mM l-glutamine and 10% (vol/vol)
heat-inactivated fetal calf serum (Invitrogen, Carlsbad,
CA) at 37°C in 5% CO2. TP53 is mutated in Daoy and is
wild-type in D283 cells [28,29]. For treatment studies, cells
were exposed to etoposide (VP-16, 1–10 μM), cisplatin
(CDDP, 5–25 μM), or vehicle (DMSO, 0.02%) control in
complete media.
Quantitative real-time RTPCR (qRT-RTPCR) analysis
Total cellular RNA was extracted with either TRIzol (Invit-
rogen, Carlsbad, CA) or RNeasy (Qiagen, Valencia, CA)
based on tissue abundance, according to the manufactur-
ers' recommendations. For reference controls, we used
commercially available RNA from human fetal brain and
human adult cerebellum (Stratagene, La Jolla, CA).   RNA
Table 1: Patient and tumor characteristics
Patient and Tumor Characteristics All Patients Patients with Tumor TAp73 
RNA < median
Patients with Tumor TAp73 
RNA > median
Age at diagnosis (median) 80 months 79 months 79 months
< 36 months old (%) 4 (12) 2 (6) 2 (6)
> 36 months old (%) 30 (88) 15 (44) 15 (44)
Sex n (%) n (%) n (%)
Male (%) 23 (68) 12 (35) 11 (32)
Female (%) 11 (32) 5 (15) 6 (18)
Metastatic (Chang) Stage n (%) n (%) n (%)
M0, non-metastatic (%) 24 (71) 11 (32) 14 (41)
M1–M3, metastatic (%) 10 (29) 6 (18) 3 (9)
Primary Resection Extent n (%) n (%) n (%)
Gross Total Resection (%) 23 (68) 12 (32) 11 (35)
Subtotal, Partial Resection or Biopsy only (%) 11 (32) 5 (15) 6 (18)
Histologic Subtype n (%) n (%) n (%)
Classic, predominant (%) 8 (24) 4 (12) 3 (9)
Desmoplastic/Nodular, predominant (%) 12 (35) 6 (18) 7 (21)
Large Cell/Anaplastic, any features (%) 14 (41) 7 (21) 7 (21)
Total 34 (100) 17 (50) 17 (50)BMC Cancer 2007, 7:127 http://www.biomedcentral.com/1471-2407/7/127
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integrity was verified on an Agilent 2100 Bioanalyzer (Agi-
lent, Palo Alto, CA).
RNA was analyzed by qRT-RTPCR performed with the
Bio-Rad iQ4 Multicolor Real-Time iCycler (Bio-Rad Labo-
ratories, Hercules, CA). Total cellular RNA was reverse
transcribed with Moloney murine leukemia virus reverse
transcriptase (Invitrogen, Carlsbad, CA) and oligo-(dT)12,
using standard methods. PCR reactions containing cDNA,
iQ Syber Green Supermix (Bio-Rad Laboratories) and
primers for TP53, full-length or 5'-terminal variant iso-
forms of TP73 were performed for 40 cycles in triplicate
(Figure 1A). Specific primers detect RNA species for full-
length human TP73  (TAp73) and 5'-terminal variants
(ΔNp73, ΔN'p73, ΔEx2p73, and ΔEx2/3p73) (Figure 1A):
TAp73 sense, 5'-CCGGCGTGGGGAAGATGG-3' and
antisense, 5'-TTGAACTGGGCCATGACAGATG-3';
ΔNp73 (and ΔN'p73) sense, 5'-ACGGCCCAGT-
TCAATCTGC-3' and
antisense, 5'-CTGGGGTGTAGGGGCTGG-3';
ΔN'p73 sense, 5'-TCGACCTTCCCCAGTCAAGC-3' and
antisense, 5'-TGGGACGAGGCATGGATCTG-3';
ΔEx2p73 sense, 5'-AGGGAACCAGACAGCACCTA-3' and
antisense, 5'-ACGTCCATGCTGGAATCCG-3';
ΔEx2/3p73 sense, 5'-CAGGCCCAGTTCAATCTGCTG-3'
and
antisense, 5'-GAGTGGGTGGGCACGCTG-3';
TP53 sense, 5'-CCATCTACAAGCAGTCACAGC-3' and
antisense, 5'-GAGTCTTCCAGTGTGAGATG-3';
GAPDH sense, 5'-AAGGTGAAGGTCGGAGTCAA-3' and
antisense, 5'-AATGAAGGGGTCATTGATGG-3'.
Because ΔNp73 lacks unique primer sequences, its relative
abundance was calculated by subtracting from the relative
copy number of ΔN'p73 (using the ΔN'p73-specific
upstream primer pair) from those of ΔNp73 and ΔN'p73
determined using the common primer pair.
Amplification products were verified by agarose gel elec-
trophoresis, melting curves, and sequencing. Gene expres-
sion was normalized internally to GAPDH  expression,
relative to control human fetal brain RNA as a tissue refer-
ence, and accounting for differences in primer efficiencies
[30]. Results from at least two separate experiments were
analyzed.
Western immunoblot analysis
Cell lysates were prepared using standard methods.
Briefly, protein was extracted from frozen tissue with boil-
ing lysis buffer (0.5% SDS, 50 mM Tris-Cl, pH 8, 5 mM
Na2EDTA) containing 2% β-mercaptoethanol for 5 min-
utes and tissue was homogenized using a PT1200CL Pol-
ytron (Kinematica, Switzerland), followed by shearing
through a 22-guage needle and clarification by brief cen-
trifugation. Yields were quantitated using the RC-DC Pro-
tein assay (Bio-Rad Laboratories, Hercules, CA). Lysates
were separated by SDS-PAGE and transferred onto PVDF
membranes for immunoblotting with antibodies against
p73 (H-79, Santa Cruz Biotechnology, Santa Cruz, CA;
and GC-15, Pharmingen, San Jose, CA), ΔNp73 (IMG-
313, Imgenex, San Diego, CA), and p53 (FL-393 or DO-1,
Santa Cruz Biotechnology), p21Waf1  (Ab-11(CP74),
Thermo Fisher Scientific, Fremont, CA), PARP (Cell Sign-
aling Technology, Danvers, MA), and β-actin (C-2, Santa
Cruz Biotechnology).
Chemiluminescent detection of primary antibody stain-
ing was performed using HRP-conjugated secondary anti-
bodies (Jackson ImmunoResearch, West Grove, PA) with
LumiGLO substrate, according to manufacturer's recom-
mendations (Cell Signaling Technologies, Beverly, MA).
Western blots were exposed to Kodak BioMax MS film
(Kodak, New Haven, CT), developed, and analyzed with
Image Station 2000R (Kodak). Alternatively, staining with
fluorescent secondary antibody (Alexa Fluor 680 nm-con-
jugated goat anti-mouse IgG, Invitrogen) was visualized
using an Odyssey infrared imaging system (LI-COR Bio-
sciences, Lincoln, Nebraska). Intensity of immunostain-
ing was quantitated using ImageQuant 5.2 (Molecular
Dynamics, Piscataway, NJ). The intensity of each protein
band was normalized to β-actin immunostaining as an
internal loading control, and compared to results in the
D283 cell line as a tissue reference. Results from at least
two separate experiments were analyzed.
Immunohistochemical analysis of primary human tumors
For immunostaining, five micron thick sections were pre-
pared from formalin-fixed paraffin embedded medullob-
lastoma specimens. Tissue sections were deparaffinized in
xylene, followed by graded hydration in 100% ethanol,
70% ethanol, and H2O. Antigen retrieval was performed
by boiling in DAKO citrate for 25 min (Dako, Carpinteria,
CA). Endogenous peroxidase was blocked with 3% H202/
Methanol for 15 min, then incubated with 20% goat
serum for 20 min. Sections were incubated with anti-p53
antibody (D07, Novocastra, Newcastle Upon Tyne, UK)BMC Cancer 2007, 7:127 http://www.biomedcentral.com/1471-2407/7/127
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for 1 hour at 25°C. This antibody is reactive for both wild-
type and mutant p53 proteins. This was followed by incu-
bation with HRP-conjugated goat anti-mouse secondary
antibody for 30 min. Washed sections were developed
using 3-amino-9-ethyl carbazole as the chromogen. The
immunostained sections were graded semi-quantitatively
for degrees of staining intensity (negative, 0; positive, 1+
to 3+) by neuropathologists blinded to clinical informa-
tion.
Gene expression and post-transcriptional gene silencing 
transfections
Daoy and D283 cell lines were transiently transfected with
expression and reporter plasmids using Lipofectin accord-
ing to manufacturer's recommendations (Invitrogen).
Expression plasmids included: the human cytomegalovi-
rus (CMV) immediate-early (IE) promoter-driven pP53-
EGFP plasmid, encoding a p53-enhanced green fluores-
cent protein (GFP) fusion protein (Clontech, Mountain-
view, CA), and CMV IE promoter-driven hemaglutinnin-
tagged human TAp73β- and Myc-tagged mouse ΔNp73β-
encoding plasmids were previously described [14,31]. In
each transfection, the expression plasmids were supple-
mented by empty vector (pcDNA3.1, Invitrogen) to
achieve an equivalent total plasmid DNA concentration.
For flow cytometry, the EGFP-expressing pmaxGFP plas-
mid (Amaxa, Gaithersburg, MD) provided transfection
controls.
Transient small interfering RNA (siRNA)-mediated silenc-
ing of TAp73 and ΔNp73 was achieved using the follow-
ing siRNAs: TAp73 (targeting a sequence in TP73 exon 3),
5'-AACGGAUUCCAGCAUGGACGU-3' [32]; ΔNp73 (tar-
geting a sequence in TP73 exon 3B to exon 4), 5'-AAC-
CUCGCCACGGCCCAGUUC-3'. Transfections with
equimolar concentrations of validated siCONTROL non-
targeting siRNA Pool#1 (Dharmacon, Lafayette, CO) pro-
vided negative controls. Daoy and D283 cells were grown
to 50% confluency in a 6-well plate and transfected for 6
hours in Opti-MEM serum-free media (Invitrogen) with
Oligofectamine Reagent, according to manufacturer rec-
ommendations (Invitrogen). Cells were allowed to
recover from transfection for 24–48 hours and were then
treated for 24 hours before harvesting for RNA or protein
isolation. The resulting expression of target and off-target
(e.g. β-actin and GAPDH) proteins were assayed by West-
ern immunoblot analysis, relative to cells transfected with
the negative control siRNA (Dharmacon).
Apoptosis detection by flow cytometry and terminal 
deoxynucleotidyl transferase-mediated biotinylated-dUTP 
nick end-labeling (TUNEL)
We monitored DNA-indices for cell cycle analysis by mul-
tiparametric flow cytometry using standard methods.
Analyses were performed using a Becton Dickinson FACS-
can flow cytometer (BD Biosciences, San Jose, CA) for the
detection of cells stained with propidium iodide (PI) and
a 488 nm laser with filter combination for fluorescein iso-
thiocyanate (FITC) and GFP. Single cell suspensions were
isolated from culture, fixed in methanol, and stained with
PI (100 μg/mL in PBS). Each histogram represents
10,000–100,000 cells for measuring DNA-index and cell
cycle. Histogram analysis was performed with the Cel-
lQuest program (BD Biosciences). We calculated the sub-
G0/G1 peak in the hypodiploid distribution below a DNA
index of one (< 2n). Because the nucleus becomes frag-
mented during apoptosis and numerous individual chro-
matin fragments may be present in a single cell, the
percentage of objects with a fractional DNA-content is
represented by the sub-G0/G1 peak. Apoptotic nuclei were
identified as a hypodiploid DNA peak, and were distin-
guished from cell debris on the basis of forward light scat-
ter and PI fluorescence.
To detect apoptotic nuclei in sub-G0/G1 peaks, a subset of
unstained cells was analyzed for DNA-fragmentation
using Frag-EL DNA fragmentation detection kit, according
to manufacturer's recommendations (Oncogene Research
Products, Cambridge, MA). Cells were also counter
stained with PI for DNA quantification. FITC signal was
detected on one channel in the logarithmic mode, while
UV fluorescence (PI) was recorded in the linear mode on
a separate channel. For each measurement, at least 10,000
cells were analyzed. We used CellQuest software for mul-
tiparametric calculations and analyses. Cut-off negative
and positive cells resulted from FITC-fluorescence isotype
control measurements for each sample.
Statistical considerations
Clinical outcomes were analyzed for progression-free and
overall survival using the method of Kaplan and Meier
(StatView, v. 4.5, Abacus Concepts, Berkeley, CA; Graph-
Pad Software, v.4; San Diego, CA). Patients were stratified
according to tumor TAp73  RNA levels, normalized to
GAPDH and relative to expression in fetal brain control
RNA. The "high" expression group contained patients
with tumor expression of TAp73 RNA greater than or
equal to the median value of all tumors analyzed. The
"low" expression group contained patients with tumor
expression of TAp73 RNA less than the median value of all
tumors analyzed. The significance of survival differences
was calculated by logrank testing, which was applied to
assess the significance of specific factors (e.g. patient strat-
ification by TP73  expression level). To determine if
expression levels correlated with other clinical and tumor
characteristics, we applied Fisher's Exact testing.BMC Cancer 2007, 7:127 http://www.biomedcentral.com/1471-2407/7/127
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Results
Medulloblastoma cell lines and primary medulloblastoma 
specimens overexpress TP73 RNA species relative to 
normal brain tissue
In order to examine the involvement of TP73 in medul-
loblastoma growth, we surveyed expression levels of
TAp73 and total ΔNp73 variants (ΔNp73,  ΔN'p73,
ΔEx2p73, and ΔEx2/3p73) using qRT-RTPCR. Compared
to human fetal brain, Daoy and D283 cell lines, as well as
adult human cerebellum overexpressed TAp73 and total
ΔNp73 RNA variants, internally normalized to GAPDH
(Figure 1B). TP53-mutant Daoy cells displayed much
higher levels of TAp73 and of total ΔNp73 RNA (9-fold ±
1 (mean ± S.E.M.) and 12-fold ± 2, respectively) than fetal
brain. D283 cells expressed even higher levels of TAp73
and total ΔNp73 (116-fold ± 35 and 74-fold ± 16, respec-
tively).
Since established cell lines in vitro differ significantly from
medulloblastomas  in vivo, we analyzed primary tumor
specimens from 34 patients. By qRT-RTPCR, the RNA
expression of TAp73 and total ΔNp73 variants was similar
among primary medulloblastoma samples but markedly
higher than cell lines (Figure 1B–C, see Additional file 1).
Primary tumors displayed 282-fold (± 65) more TAp73
and 194-fold (± 36) more total ΔNp73 RNA than human
fetal brain.
To provide an additional tissue control, we analyzed TP73
5'-variants in RNA from human adult cerebellum. Com-
pared to human fetal brain, adult cerebellum also dis-
played overexpression of TAp73 and total ΔNp73 RNA
(24-fold ± 6 and 48-fold ± 5, respectively) (Figure 1B).
Importantly, primary medulloblastoma samples
expressed about 10-fold more TP73  RNA than normal
adult cerebellum (Figure 1B). Of the four control tissue
controls, male and female fetal brain RNA (Stratagene)
revealed similar TP73 expression profiles. As shown in
Figure 1B, adult cerebellum expressed 10 to 100-fold
more TAp73 and ΔNp73 RNA compared to human fetal
brain controls. We also examined TP73 RNA expression in
human adult frontal cortex (Stratagene) by qRT-RTPCR,
but found minimal expression of TAp73 or ΔNp73 tran-
scripts (data not shown).
Since the effects of p73 isoforms likely reflect their ability
to interact with p53, we assessed TP53 expression using
primers in exons 5 and 7 to detect all known TP53 splice
variants (Figure 1B, see Additional file 1). The Daoy cell
line, which harbors a p53 mutation (C242F), expressed
TP53 RNA at a level similar to human fetal brain, 1.1-fold
(± 0.42), but 15-fold (± 2.0) more than human adult cer-
ebellum. The D283 cell line expressed TP53 RNA at much
lower levels than human fetal brain, 0.05-fold (± 0.016)
and 0.43-fold (± 0.14) relative to human adult cerebel-
lum. Primary medulloblastoma specimens displayed
TP53 levels 1.4-fold (± 0.12) higher than in human fetal
brain, and 12-fold (± 1.0) higher than in human adult cer-
ebellum (Figure 1B). TP53 copy numbers in cell lines were
at least one log lower than either TAp73 or total ΔNp73
levels, whereas in primary tumors TP53 was at least two
logs lower than either TAp73 or total ΔNp73.
Primary tumors and cell lines overexpress TAp73 and 
ΔNp73 proteins
In order to examine expression of p73 proteins in estab-
lished cell lines and primary medulloblastoma samples,
we employed monoclonal (GC-15) and polyclonal (H-
79) antibodies, which recognize full-length TAp73 and
amino-truncated ΔNp73 [33], and a ΔNp73-specific mon-
oclonal antibody (IMG-313) (Figure 2A–B, see Additional
file 2). Protein levels were internally normalized to β-actin
expression as a loading control and compared to expres-
sion in the D283 cell line as a reference.
The H-79 polyclonal antibody, raised against a conserved
amino-terminal peptide sequence, recognizes the major
carboxy-terminal variants of TAp73 (TAp73α, 75–80 kDa;
and TAp73β, 60–65 kDa) and of ΔNp73 (ΔNp73α, 70–75
kDa; and ΔNp73β, 50 kDa) [34]. Both established medul-
loblastoma cell lines, Daoy and D283, exhibited signifi-
cant, although different levels of TAp73 and ΔNp73,
relative to β-actin (Figure 2C). Primary tumor specimens
(n = 8), in contrast, exhibited more ΔNp73 (1.7-fold
D283 levels (± 0.34)) compared to TAp73 (0.55-fold ±
0.2).
The GC-15 monoclonal antibody, raised against a con-
served carboxy-terminal peptide sequence, found in p73β
isoforms, also detected comparable levels of TAp73 pro-
tein in established cell lines and in primary medulloblas-
toma samples (Figure 2A–B). To confirm the identity of
putative ΔNp73 bands, we used the ΔNp73-specific IMG-
313 antibody (Figure 2A–B). Based on their predicted
molecular weights, the other detected isoforms presuma-
bly represent other carboxy-terminal variants as reported
by others [35]. The equivalent expression of TAp73 and
ΔNp73 protein in D283 cells resembled its RNA expres-
sion pattern by qRT-RTPCR. In contrast, Daoy cells
expressed slightly more TAp73 than ΔNp73 protein, and
primary tumor samples displayed higher levels of ΔNp73
compared to TAp73 protein.
Primary medulloblastoma specimens and cell lines dis-
played variable p53 protein levels (Figure 2A–B, see Addi-
tional file 3). Daoy cells express high levels of mutant p53.
The higher p53 level in Daoy cells suggests decreased turn-
over by MDM2-mediated degradation as commonly seen
with many mutant p53 proteins. D283, which is wild-type
for TP53, expresses much lower levels of p53 protein atBMC Cancer 2007, 7:127 http://www.biomedcentral.com/1471-2407/7/127
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baseline (Figure 2C). The relative p53 protein levels in
established cell lines and primary medulloblastoma are
similar to their pattern of TP53 RNA expression. Using
antibodies with differing affinities precluded a direct com-
parison of p53 and p73 protein levels.
Although  TP53  RNA expression did not correlate with
clinical outcome, immunohistochemical staining inten-
sity of p53 protein (scored > 2+) in paraffin-embedded
formalin-fixed specimens was significantly associated
with worse progression-free survival (PFS) (p < 0.035, Fig-
ure 3). These findings underscore the central importance
of p53, which can interact with various p73 isoforms.
Overall and progression-free survival are associated with 
TAp73 overexpression
For the entire group of patients studied, the median PFS
was 35.4 months (range 4.0 – 88.3; 38.1 ± 4.5 months
(mean ± S.E.M.)). We analyzed outcome among subsets
of patients with respect to clinical variables such as age,
extent of primary resection, or metastatic disease at diag-
nosis. As established in other series, those children less
than 36 months old (p < 0.160 and p < 0.126 for overall
survival (OS) and progression-free survival (PFS) by
logrank, respectively) or with metastatic disease (M-posi-
tive Chang stage; p < 0.044 (OS) and p < 0.024 (PFS)) dis-
played a trend toward worse OS and PFS, but did not
achieve statistical significance (Figure 4A–B). OS and PFS
were not significantly associated with patient sex, degree
of initial resection, or chemotherapy regimen.
The association of TP73 expression with clinical outcome
in neuroblastoma, the most common malignant solid
tumor of childhood, prompted our analysis of the rela-
tionship between TP73 RNA and survival in medulloblas-
toma patients. When stratified by tumor TAp73 RNA
levels, higher expression was associated with better PFS (p
< 0.052) and OS (p < 0.070) (Table 1; Figure 4C–D). We
also examined RNA expression of TP53, TAp73, or ΔNp73
variants, and histologic subtype, but found no statistically
significant association with OS or PFS. TP53 and TP73
RNA levels did not correlate with other prognostic factors
such as patient age, metastatic status, or extent of resec-
tion, with p values ranging from 0.35 to 1.00 (Fisher's
Exact test).
Genotoxic stress induces TP73 expression in 
medulloblastoma cell lines
Because the analyzed tumor specimens were obtained
before genotoxic treatment, gene expression levels do not
reflect the activity of p53 and p73 isoforms. Therefore, we
used medulloblastoma cell lines to assay responses to
genotoxic stress in the form of chemotherapeutic agents
used to treat medulloblastoma clinically (cisplatin
(CDDP), etoposide (VP-16)) and another agent, doxoru-
Primary medulloblastoma specimens and medulloblastoma  cell lines overexpress TAp73 and ΔNp73 proteins Figure 2
Primary medulloblastoma specimens and medullob-
lastoma cell lines overexpress TAp73 and ΔNp73 
proteins. Western immunoblot analysis of p53, TAp73, and 
ΔNp73 protein expression in: (A) established medulloblast-
oma cell lines, Daoy and D283MED (D283), and (B) primary 
medulloblastoma specimens. Immunoblots for p53 (FL-393) 
or p73 proteins (H-79, GC-15, and IMG-313) were stripped 
and re-probed for β-actin (C-2) to control for protein load-
ing. Columns marked with numbers 1–8 represent Western 
blots of eight different primary medulloblastoma specimens. 
Additional bands presumably represent additional carboxy-
terminal isoforms of TAp73 and ΔNp73. Relative migration 
of molecular weight standards is shown at left. Shown are 
representative blots from at least 3 experiments, normalized 
to ß-actin (mean ± S.E.M.).   (C) Primary medulloblastoma 
(MB) specimens and medulloblastoma cell lines display signifi-
cant expression of TAp73, ΔNp73, and p53 proteins as quan-
titated on Western blots. Shown are representative blots 
from at least 3 experiments, normalized to ß-actin (mean ± 
S.E.M.).BMC Cancer 2007, 7:127 http://www.biomedcentral.com/1471-2407/7/127
Page 8 of 16
(page number not for citation purposes)
Intensity of p53 immunostaining correlates with overall survival Figure 3
Intensity of p53 immunostaining correlates with overall survival. Examples of medulloblastoma sections displaying 
(A) 1+, (B) 2+, and (C) 3+ intensity of p53 immunostaining. (D) Kaplan-Meier survival analysis illustrating association of 2+ 
and 3+ intensity with adverse progression-free survival (p < 0.035 by logrank testing).BMC Cancer 2007, 7:127 http://www.biomedcentral.com/1471-2407/7/127
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bicin, previously studied for TP73 induction (Figure 5A).
When exposed to cytotoxic concentrations of these agents,
TP53 and TP73 RNA levels, especially the ΔN'p73 species,
increased in D283 cells (Figure 5B). Although less p53
induction was observed in TP53  mutant Daoy cells,
increased  TP73  levels including ΔN'p73 were detected
(Figure 5C). These data indicate that in addition to post-
translational stabilization, p73 levels are regulated at least
in part through chemotherapy-induced p73 RNA tran-
scription.
D283 and Daoy cells were also used for transfection stud-
ies to determine the effects of overexpressed TAp73 and
ΔNp73. Treatment with VP-16 stabilized p53 levels in
D283 cells (Figure 5D). We examined the effects of
increased p53, TAp73, and ΔNp73 levels by transient
Medulloblastoma survival is associated with TAp73 overexpression Figure 4
Medulloblastoma survival is associated with TAp73 overexpression. Kaplan-Meier analysis reveals trends toward 
adverse outcome associated with (A)  age less than 36 months (p < 0.126 by logrank), and  (B)  metastatic (M+) disease at 
diagnosis (p < 0.024); while revealing  (C)  a trend toward better PFS (p < 0.052) and (D)  better OS and in patients whose 
tumors display higher TAp73 RNA levels (p < 0.070). Patients were stratified (High vs. Low) according to tumor TAp73 lev-
els, normalized to GAPDH and relative to fetal brain control. High = greater than or equal to the median tumor expression of 
TAp73 RNA. Low = less than the median tumor expression of TAp73 RNA.BMC Cancer 2007, 7:127 http://www.biomedcentral.com/1471-2407/7/127
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transfection with expression plasmids. Transient trans-
fected p53, TAp73, and ΔNp73 could be readily distin-
guished on Western blots of D283 and Daoy cell lines
(Figure 5C–D).
Genotoxic agents induce TP73 expression and apoptosis in medulloblastoma cell lines Figure 5
Genotoxic agents induce TP73 expression and apoptosis in medulloblastoma cell lines. (A)  Chemotherapeutic 
agents (cisplatin (CDDP) 1 μM, etoposide (VP-16) 10 μM, and doxorubicin (DOXO) 1 μM) induce TP73 expression in Daoy 
cells, especially ΔN’p73 species, as determined by qRT-RTPCR normalized to GAPDH expression.  (B)  CDDP-treated (1, 5, 
and 25 μM) D283 cells display induction of TP53 and TP73 RNA expression (including ΔN’p73 species) - similar to results 
observed in CDDP-treated Daoy cells. Western immunoblots reveal that (C) Daoy cells and (D)  D283 cells transiently trans-
fected with p53-GFP expression plasmid increase expression of tagged p53-GFP protein (at a higher apparent molecular weight 
than native p53), as well as the p53/p73 target, p21Waf1(arrows, upper panels). Treatment with etoposide (VP-16, 1.5 μM) 
stabilizes wild-type p53 protein.  Transient transfection with either TAp73 or ΔNp73 expression plasmids also increased 
respective protein levels, normalized to ß-actin loading control. (arrows lower panels).  BMC Cancer 2007, 7:127 http://www.biomedcentral.com/1471-2407/7/127
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Chemotherapy and overexpressed p53 induce apoptosis
We investigated whether p53 induces apoptosis in medul-
loblastoma cells exposed to chemotherapeutic agents.
Expression plasmid transfections also permitted flow
cytometric analysis of the cell cycle distribution of fluores-
cently immunolabeled TAp73β-, ΔNp73β-, and p53-over-
expressing transfectants. VP-16-induced changes in
apoptosis were determined by flow cytometric quantita-
tion of cells in sub-G0/G1 fractions, which was confirmed
by TUNEL analysis (see Additional file 4). Similar results
were obtained with CDDP and UV irradiation (data not
shown).
TP53 mutant Daoy cells treated with VP-16 increased their
apoptotic sub-G0/G1 population to 22.6% compared to
7.2% in untreated controls, illustrating VP-16 induced
apoptosis in the absence of active p53 (Figure 6A). Over-
expression of transfected wild-type  p53 in Daoy cells
caused increased apoptosis (10.1% in sub-G0/G1), com-
pared to controls (7.2%) (Figure 6A). VP-16 treatment of
p53-expressing Daoy transfectants further increased apop-
tosis (29.4%) (Figure 6A). These data indicate that trans-
fected p53 expression partially restored p53 function in
TP53-mutant Daoy cells.
When exposed to VP-16, D283 controls (transfected with
a GFP-expressing control plasmid) underwent increased
apoptosis as indicated by an increased fraction of cells in
sub-G0/G1, from 7.0 to 11.3%, (Figure 6B). These results
indicate that VP-16 induces apoptosis, as described for
other neuroepithelial cell types with wild-type p53. Over-
production of p53 in D283 cells by transfection of a GFP-
tagged p53 expression plasmid increased apoptosis
(12.0% in sub-G0/G1) compared to controls (7.0%) (Fig-
ure 6B). VP-16 treatment of p53-transfected D283 cells
further increased the sub-G0/G1 population to 18.6% (Fig-
ure 6B).
Overexpression of p53 in transfected Daoy cells increased
expression of p21Waf1 protein, relative to control maxGFP-
transfected cells (upper panels, Figure 5C). VP-16 treat-
ment of p53-overexpressing D283 cells also increased
p21Waf1 protein demonstrating the activity of transfected
p53 (upper panels, Figure 5D).
Overexpression of TAp73β or ΔNp73β induces apoptosis
We examined the effects of TAp73 overexpression on sur-
vival. TAp73β overexpression increased apoptosis to
19.4% from 7.0% in GFP-control transfected wild-type
TP53 D283 cells, even in the absence of genotoxic stress.
VP-16 treatment of TAp73β transfectants resulting in fur-
ther enhancement of chemosensitivity with 37.2% in sub-
G0/G1 compared to 11.3% treated control and 19.4% in
untreated TAp73β transfectants (Figure 6). Transfected
TAp73β induced apoptosis as effectively as transfected
p53 (Figure 6A). The sub-G0/G1  population in p53
mutant Daoy cells transfected with TAp73β did not differ
significantly from control transfectants under basal condi-
tions (Figure 6B).
We next asked whether ΔNp73 affects survival in medul-
loblastoma cells. Rather than anti-apoptotic effects,
ΔNp73β overexpression increases apoptosis to 17.0%
compared to 7.0% in GFP-control transfected D283 (Fig-
ure 6A). Transfection of ΔNp73β in D283 also increased
apoptosis in response to VP-16-treated D283 (29.8% in
sub-G0/G1) (Figure 6A). Neither of these effects was
observed in transfected p53 mutant Daoy cells. These data
suggest that apoptosis and chemosensitization induced by
TAp73β and ΔNp73β, as in D283 cells, require wild-type
p53.
TAp73 induces apoptosis of medulloblastoma cell lines Figure 6
TAp73 induces apoptosis of medulloblastoma cell 
lines. Histograms summarizing flow cytometric analysis of 
cell cycle distributions of: (A) transfected Daoy cell line, 
illustrating the sub-G0/G1 peak representing apoptotic 
nuclei; and (B)  transfected D283 cell line in sub-G0/G1, with 
plasmids and treatment with VP-16 (1.5 μM), as indicated.  Y-
axis, % of cells with apoptotic features by flow cytometry; X-
axis, transfected plasmid(s) and culture conditions. Western 
immunoblots also reveal that  (C) Daoy cells and  (D) D283 
cells transiently transfected with isoform-specific siRNA 
reveal knockdown of their respective protein levels.  D283 
knockdowns reduced protein expression of the p53/p73 tar-
get, p21Waf1, and cleavage of PARP (arrows).BMC Cancer 2007, 7:127 http://www.biomedcentral.com/1471-2407/7/127
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As noted with p53 overexpression, transient transfection
with expression plasmids encoding TAp73β or ΔNp73β
resulted in increased protein expression of the p53/p73
target gene p21Waf1. Overexpression of TAp73β resulted in
a comparable increase of p21Waf1 expression in Daoy cells
and untreated D283 cells, relative to control transfectants
(lower panels, Figure 5C–D). Overexpression of ΔNp73β
also increased p21Waf1 protein expression (lower panels,
Figure 5C–D). Treatment of p53-, TAp73β – and ΔNp73β-
transfected D283 cells with VP-16 revealed similar induc-
tion of p21Waf1 (Figure 5D). These results demonstrate the
transcriptional activity of overexpressed TP73 isoforms in
medulloblastoma cell lines.
Knockdown of TAp73 or ΔNp73 reduces target gene 
expression and apoptosis
Transient transfection of Daoy and D283 cells with iso-
form-specific siRNAs decreased TAp73 and ΔNp73 pro-
tein expression by Western blot analysis (Figure 6C–D). In
D283 transfectants, TAp73 siRNA decreased the protein
expression of the p53/p73 target gene p21Waf1 (Figure
6D). As an indicator of decreased apoptosis, PARP cleav-
age was also decreased by TAp73 knockdown in D283
(Figure 6D). In contrast, D283 cells transfected with
ΔNp73 siRNA did not display p73 target gene induction
or PARP cleavage in D283 (Figure 6D). Reducing ΔNp73
expression siRNA resulted in decreased p21Waf1 protein as
seen in TAp73 knockdowns (Figure 6D). These knock-
down data complement the results of overexpression and
apoptosis assays.
Discussion
We have determined that primary medulloblastoma spec-
imens and cell lines overexpress full-length TAp73 and the
amino-terminal truncated variants of TP73  (ΔNp73,
ΔN'p73, ΔEx2p73, and ΔEx2/3p73) at levels in excess of
those found in fetal brain and normal adult cerebellum.
We have also shown that adult cerebellum express more
TAp73 and 5'-terminal variant RNAs than human fetal
brain. This is consistent with results from studies in
murine brain showing that the relative balance of TP73
expression appears to shift during development with
increasing overall levels [14]. Normal neuronal differenti-
ation requires a balance between TAp73 and ΔNp73
[14,15]. While ΔNp73 is necessary for adult neuronal sur-
vival, levels in excess of these physiologic anti-apoptotic
levels may prevent normal cell death during development,
following growth factor withdrawal, or in response to gen-
otoxic stress such as chemotherapeutic agents [14].
Studies of TP73 expression in mature CNS have been lim-
ited. In adult mouse brain, TP73 is most highly expressed
in the cerebellum [36]. Other studies of murine models
have described the crucial role of ΔNp73 in survival of
neurons in the CNS [37,38]. In contrast, TP73 expression
and function in normal human brain has not been fully
characterized. Others have reported higher TP73 expres-
sion in human tumor tissue than in normal brain tissue
[39-41]. While human fetal brain reportedly expresses
high levels of ΔNp73 in Cajal-Retzius cells [42], adult cor-
tical and hippocampal neurons apparently express signif-
icant levels of both TAp73 and ΔNp73 [43]. While human
cerebellum has not been previously studied, our qRT-
RTPCR results confirm TP73 expression in non-neoplastic
CNS tissue. Aberrant TP73 expression in the cerebellum
may divert developing neurons from normal differentia-
tion, leading to uncontrolled proliferation and medullob-
lastoma formation.
We have also confirmed high levels of expression of
TAp73 and ΔNp73 proteins in the same tumors and cell
lines. Among different cell types, the apparent discrepancy
between expression of TP73 variants at the RNA and pro-
tein levels suggests that post-translational modifications
also contribute to observed levels. Like other transcription
factors, TP73 variants are regulated by a variety of positive
and negative networks involving: E2F1, MDM2, Sumo-1,
c-Abl, NEDL2, and other DNA damage response factors
[21,44]. Such complex regulatory influences probably
account for the dynamic expression levels of TP73, as seen
with p53.
Our analysis of primary medulloblastoma was limited to
those specimens with sufficient quantities available as
freshly snap frozen tissue suitable for analysis. This fact
may represent an unintended selection bias. However,
more importantly, none of our findings correlates with
histologic subtype or clinical features. Nonetheless, we
detected trends toward favorable overall and progression-
free survival of patients whose tumors display higher lev-
els of TAp73 RNA, similar to reports in certain adult
tumor types [16-19,39]. Future inclusion of additional
patients and longer follow-up may increase the strength of
the association between TP73 and outcome.
TP73 overexpression in medulloblastoma samples com-
pared to normal brain provides potential evidence for p73
isoforms in the growth and treatment response of medul-
loblastoma. In contrast to normal brain tissue, primary
tumor specimens and established medulloblastoma cell
lines overexpress both TAp73 and ΔNp73 proteins, con-
sistent with dysregulation of developmental expression
and a possible contribution to their neoplastic phenotype.
Functional studies of TAp73 and ΔNp73 have revealed
differential effects in response to genotoxic stress [16,44-
46]. TAp73 induces arrest and apoptosis, while in most
systems ΔNp73 counteracts these pathways in response to
ionizing radiation and genotoxic agents in vitro [as
reviewed in [47]]. In other cell types, ΔNp73 induces
apoptosis instead, underscoring the complexity of p73BMC Cancer 2007, 7:127 http://www.biomedcentral.com/1471-2407/7/127
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isoform function. The frequency and degree of TP73 over-
expression in primary medulloblastoma strongly suggests
the acquisition of selective advantage(s). Higher relative
levels of TAp73 may enhance the apoptotic response of
medulloblastoma.
Since p73 isoforms interact with p53 and can activate
common target genes, overexpression of TAp73 and
ΔNp73 may affect medulloblastoma growth via interac-
tion with TP53 and may have functional significance in
medulloblastoma. The association between apparent p53
overexpression and clinical outcome in medulloblastoma
may not reflect the effects of wild-type p53. Since mutant
or dominant negative p53 isoforms are also detected by
the nonselective antibodies used, conclusions regarding
potential interactions between p53 and p73 cannot be
drawn in the absence of TP53 sequencing.
Etoposide and cisplatin are among the chemotherapeutic
drugs important in the treatment of medulloblastoma,
and known to activate TAp73. Cisplatin reportedly
increases p73 levels by post-translational stabilization,
but we detected increased p73 RNA species, most notably
the ΔN'p73 variant, suggesting a component of transcrip-
tional induction. Our results indicate that chemotherapy-
induced genotoxic stress induces apoptosis in D283 and
Daoy cells. Our results are consistent with studies of other
wild-type p53 cell types, including neuroepithelial cells,
indicating that VP-16 induces apoptosis in a p53-related
manner [48-50]. Furthermore, p53 overexpression alone
induces apoptotic cell death, indicating that overexpres-
sion of p53 can overcome endogenous negative regula-
tion in D283 cells and TP53-mutation in Daoy cells.
To address the functional significance of TAp73 and
ΔNp73 overexpression, we transiently transfected medul-
loblastoma cell lines and examined their survival. Medul-
loblastoma cell lines with wild-type  and mutant TP53
displayed distinct effects of TP73 overexpression. In addi-
tion to high levels of basal TAp73 and ΔNp73 in D283, we
found that exogenous TAp73β and ΔNp73β increased
apoptosis, especially in response to VP-16. In TP53
mutant Daoy cells, overexpressed TAp73β and ΔNp73β
had little effect, even in response to VP-16.
In general, overexpression of p53, TAp73β, and ΔNp73β
each induced expression of p53/p73 target genes associ-
ated with arrest and apoptosis. As expected, knockdown
of p53 or TAp73 was associated with reduced expression
of these proteins. These results support our TUNEL and
flow cytometric data, providing evidence that modulation
of p53 and p73 functions can influence chemosensitivity
in medulloblastoma. These data suggest that TAp73 regu-
lates apoptosis in medulloblastoma, but is dependent on
the p53 status. One possible explanation for this effect is
that some forms of mutant p53 can hetero-oligomerize
with and inactivate TAp73 [33,51]. Thus, transfected
TAp73 may be sequestered in inactive oligomers with
mutant p53 preventing activation of p73 pro-apoptotic
target genes. In addition to direct interaction with p53,
p73 isoforms co-regulate shared downstream transcrip-
tional targets of p53.
The initial depiction of ΔNp73 and TAp73 as either anti-
or pro-apoptotic appears oversimplified [as reviewed in
[47]]. In fact, various chemotherapeutic agents can induce
ΔNp73 expression in neoplastic cell lines, suggesting a
role in apoptotic response [52,53]. Others have noted that
constitutive expression of ΔNp73 isoforms can either
resist or increase apoptosis while inducing p53 target gene
expression [54,55]. The pro-apoptotic effects of ΔNp73
have been previously described and may reflect cell type-
dependent factors other than specific interactions with
p53. These emerging data indicate that the diversity of p73
functions depend upon the cellular context so that the
pattern of isoforms expressed may cause pro- or anti-
apoptotic effects. These factors add further to the com-
plexity of interpreting the chemosensitizing effects and
overabundance of p73 isoforms that we have observed in
medulloblastoma. Nonetheless, our results indicate that
TAp73 and ΔNp73 are overexpressed in primary medul-
loblastoma and demonstrate pro-apoptotic effects similar
to those of p53, which may provide mechanisms for mod-
ulating tumor cell survival and clinically relevant prog-
nostic information.
Conclusion
Our analysis of 34 medulloblastoma patient specimens
and the medulloblastoma cell lines Daoy and D283 dem-
onstrates significant expression of full-length, TAp73, and
amino-terminal-truncated, ΔNp73, TP73 RNA transcripts
and protein. Although the correlation between TP73 RNA
expression and patient survival did not achieve statistical
significance, there was a trend toward improved overall
and progression-free survival in patients whose tumors
exhibited high expression of TAp73 RNA. Furthermore, by
overexpressing or knocking-down TAp73 or ΔNp73
expression, we have implicated TP73 isoforms in chem-
oresponsiveness of medulloblastoma. These results sug-
gest that expression of the TP73  isoform TAp73 in
medulloblastomas may be useful as a prognostic marker
for patient survival. Our results also suggest that therapeu-
tic strategies that increase TP73 expression may be useful
to augment responsiveness of medulloblastomas to
chemotherapy.
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